Abstract
Malaria is the worldwide infectious disease causing significant losses of human lives every year. The deployment of artemisinin-based combination therapies (ACTs) has helped to reduce the losses caused by malaria. However, resistance to ACTs evolved especially by Plasmodium falciparum occurs and becomes more and more threats for human lives. Up to now, there is no effective way to solve this drug-resistance problem. Here we propose a new ACT, which contains traditional ACT plus iron supplement, so-called ferrous ACT (FACT). The FACT is promising to become a safe and effective new formulation to combat ACT resistance malaria, helping WHO reach its 2030’s Malaria Control Goal.
Competing Interest Statement
The authors have declared no competing interest.
Footnotes
Figure 1 revised
Copyright
The copyright holder for this preprint is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.